Loading quotes...
Forecast
The analysts' average price target is €101.11 (+150.21%). The median is €106.83 (+164.37%).
| Buy |
Â
16 |
| Hold |
Â
6 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Arrowhead: positive Phase‑1/2a topline data for dual RNAi therapy ARO‑DIMER‑PA
Arrowhead reports preliminary topline results from the Phase‑1/2a study of ARO‑DIMER‑PA, an RNAi therapeutic designed to simultaneously silence PCSK9 and APOC3. After a single dose, mean maximal reductions of 72% for PCSK9 and 88% for APOC3 were observed; LDL cholesterol fell by 54% and triglycerides by 73%. Dose escalation proceeded up to 400 mg; the most common adverse events were injection‑site reactions and headache, and there were no drug‑related serious adverse events. The study is ongoing with multiple‑dose cohorts, and additional data are expected to be presented at an upcoming conference. » More on de.investing.com
Arrowhead prepares launch of Plozasiran and highlights strong SHASTA data
At the Cantor Fitzgerald conference, Arrowhead presented launch plans for Plozasiran and emphasized pooled SHASTA-3/4 data showing up to 81% triglyceride reduction and a 78% reduction in acute pancreatitis events, along with a favorable safety profile. The company plans to expand its field force from the current 5,000–6,000 to about 20,000 healthcare providers, favors home administration, and does not intend to out-license in the U.S. A list price of $45,000 (as with REDEMPLO for FCS) has reportedly not faced reimbursement pushback so far; a Priority Review Voucher is expected to bring the launch forward by four months. Arrowhead positioned Plozasiran as an easy-to-dose alternative to Olezarsen and sees large market potential in high-risk SHTG patients. » More on de.investing.com
Arrowhead will apply for FDA approval for Plozasiran in severe hypertriglyceridemia
Arrowhead presented positive phase-3 data on Plozasiran at the ESC Congress (studies SHASTA-3 and SHASTA-4): in 757 patients the drug reduced triglyceride levels versus placebo by 79% and 81% after 12 months. More than 90% of Plozasiran patients reached triglyceride levels under 500 mg/dL, and over half under 150 mg/dL. In a pooled analysis Plozasiran reduced acute pancreatitis events by 78% (by 91% in high‑risk patients). Arrowhead plans to submit a supplemental new drug application (sNDA) to the FDA by the end of 2026 and to use an acquired Priority Review Voucher; the safety profile showed treatment‑related events comparable to placebo. » More on de.investing.com
Arrowhead Pharmaceuticals becomes a commercial biopharma company with RNAi therapeutics
Arrowhead Pharmaceuticals develops highly precise RNAi therapeutics that selectively silence disease-causing genes and is leveraging a broad pipeline for commercialization. The company is shifting from a research operation to a revenue-generating provider with established partnerships with global pharmaceutical companies. With novel treatments in the cardiometabolic area, Arrowhead is targeting potentially multi-billion-dollar markets. » More on finanzen.net
Arrowhead beats revenue forecasts in Q3 thanks to rapid launch of REDEMPLO
Arrowhead reported revenue of $75.2 million in the third quarter of 2026, significantly exceeding expectations, while net loss widened to $1.36 per share. Revenue growth was driven by collaboration income and initial commercial sales of REDEMPLO; prescription volume and partnership revenues from Sarepta, Novartis and Madrigal rose markedly. Phase‑III studies in severe hypertriglyceridemia (SHTG) met all endpoints, and a supplemental approval filing is planned before the end of 2026, with management viewing SHTG as the next major growth driver. Arrowhead is expanding its sales force and pipeline but remains unprofitable as R&D and SG&A expenses increase; the stock reacted positively and approached its 52‑week high. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 33.37M | 84.73% |
| Gross profit | 25.57M | 88.30% |
| Net profit | -377.86M | 1,767.08% |
| EBITDA | -379.12M | 792.98% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.14B |
Number of shares | 141.25M |
52-week high/low | €86.82 - €33.70 |
| Dividends | No |
Beta | 1.37 |
P/E ratio | -9.37 |
PEG ratio | -0.01 |
P/B ratio | 134.18 |
P/S ratio | 14.97 |
Company profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
| Name | Arrowhead Pharmaceuticals |
| CEO | Christopher R. Anzalone |
| Headquarters | Pasadena,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 12/16/1993 |
| Employees | 711 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ARWR |
London Stock Exchange | 0HI3.L |
Frankfurt | HDP1.F |
DĂĽsseldorf | HDP1.DU |
London | 0HI3.L |
SIX | HDP1.SW |
MĂĽnchen | HDP1.MU |